Literature DB >> 30633946

The psychomotor vigilance task: Role in the diagnosis of hepatic encephalopathy and relationship with driving ability.

Chiara Formentin1, Michele De Rui1, Mirko Zoncapè1, Silvia Ceccato1, Lisa Zarantonello1, Marco Senzolo2, Patrizia Burra2, Paolo Angeli1, Piero Amodio1, Sara Montagnese3.   

Abstract

BACKGROUND & AIMS: Hepatic encephalopathy (HE) is a syndrome of decreased vigilance and has been associated with impaired driving ability. The aim of this study was to evaluate the psychomotor vigilance task (PVT), which is used to assess both vigilance and driving ability, in a group of patients with cirrhosis and varying degrees of HE.
METHODS: A total of 145 patients (120 males, 59 ± 10 years, model for end-stage liver disease [MELD] score 13 ± 5) underwent the PVT; a subgroup of 117 completed a driving questionnaire and a subgroup of 106 underwent the psychometric hepatic encephalopathy score (PHES) and an electroencephalogram (EEG), based on which, plus a clinical evaluation, they were classed as being unimpaired (n = 51), or as having minimal (n = 35), or mild overt HE (n = 20). All patients were followed up for an average of 13 ± 5 months in relation to the occurrence of accidents and/or traffic offences, HE-related hospitalisations and death. Sixty-six healthy volunteers evenly distributed by sex, age and education served as a reference cohort for the PVT.
RESULTS: Patients showed worse PVT performance compared with healthy volunteers, and PVT indices significantly correlated with MELD, ammonia levels, PHES and the EEG results. Significant associations were observed between neuropsychiatric performance/PVT indices and licence/driving status. PVT, PHES and EEG results all predicted HE-related hospitalisations and/or death over the follow-up period; none predicted accidents or traffic offences. However, individuals with the slowest reaction times and most lapses on the PVT were often not driving despite having a licence. When patients who had stopped driving for HE-related reasons (n = 6) were modelled as having an accident or fine over the subsequent 6 and 12 months, PVT was a predictor of accidents and traffic offences, even after correction for MELD and age.
CONCLUSIONS: The PVT is worthy of further study for the purposes of both HE and driving ability assessment. LAY
SUMMARY: Hepatic encephalopathy (HE) is a complication of advanced liver disease that can manifest as excessive sleepiness. Some patients with HE have been shown to have difficulty driving. Herein, we used a test called the Psychomotor Vigilance Task (PVT), which measures sleepiness and can also be used to assess driving competence. We showed that PVT performance is fairly stable in healthy individuals. We also showed that PVT performance parallels performance in tests which are commonly used in cirrhotic patients to measure HE. We suggest that this test is helpful in quantifying HE and identifying dangerous drivers among patients with cirrhosis.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Driving; Hepatic encephalopathy; Psychomotor Vigilance Task

Year:  2019        PMID: 30633946     DOI: 10.1016/j.jhep.2018.12.031

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  2 in total

Review 1.  Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy -current validation level and practical use.

Authors:  Mads Kingo Guldberg Hansen; Kristoffer Kjærgaard; Lotte Lindgreen Eriksen; Lea Ladegaard Grønkjær; Anne Catrine Daugaard Mikkelsen; Thomas Damgaard Sandahl; Hendrik Vilstrup; Karen Louise Thomsen; Mette Munk Enok Lauridsen
Journal:  Metab Brain Dis       Date:  2022-02-01       Impact factor: 3.584

2.  A Field Study on Safety Performance of Apron Controllers at a Large-Scale Airport Based on Digital Tower.

Authors:  Jianping Zhang; Xiaoqiang Tian; Jian Pan; Zhenling Chen; Xiang Zou
Journal:  Int J Environ Res Public Health       Date:  2022-01-31       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.